Loss of ABO Antigens in Haematological Malignancies

Tina Bianco-Miotto
B.Sc., B.Hlth.Sc. (Hons.)

A thesis submitted in total fulfillment of the requirements for the degree of Doctor of Philosophy

Department of Medicine
University of Adelaide
Adelaide, South Australia

May, 2002
Chapter 1 Introduction

1.1 Overview

1.2 Haematopoiesis

1.3 Leukaemia

1.3.1 Causes of Leukaemia

1.3.2 Types of Leukaemia

1.3.2.1 Lymphoid Leukaemia

1.3.2.2 Myeloid Leukaemia

1.3.2.3 Myelodysplastic Syndromes

1.4 The ABO Blood Group System

1.4.1 The Structure and Biosynthesis of the A, B and H Antigens

1.4.2 The Genes Encoding the Glycosyltransferases

1.4.3 The Bombay Phenotype and Secretor Status

1.4.4 Cloning and Regulation of the ABO Gene

1.4.5 Polymorphisms of the ABO Gene

1.4.5.1 A Alleles

1.4.5.2 B Alleles

1.4.5.3 O Alleles

1.4.5.4 Weak A or B Alleles

1.4.5.5 The Cis-AB and B(d) Allele

1.4.5.6 Hybrid Alleles
1.4.5.7 Allelic Variation in Untranslated Regions of the ABO Gene 25
1.4.5.8 Allelic Variations in the ABO Intron Sequence 27
1.4.5.9 Utilising the Allele Polymorphic Differences for Genotyping 29
1.4.6 ABH Antigen Expression in Adult Tissues and Embryonic Development 29
1.4.7 Alterations of ABH Antigen Expression in Solid Tumours 30
1.4.8 Loss of ABH Antigens in Haematological Malignancies 32
1.5 Genetic and Epigenetic Changes in Cancer Development
1.5.1 CpG Islands 34
1.5.2 Methylation and Transcription
1.5.2.1 X-Inactivation and Imprinting 36
1.5.2.2 Transfection Experiments 37
1.5.2.3 Methylation Mechanisms Which Affect Gene Expression 38
1.5.3 Alterations of Methylation in Cancer
1.5.3.1 Hypomethylation and Cancer 39
1.5.3.2 Levels of DNMTs 40
1.5.3.3 Targets for Mutation 40
1.5.3.4 Calcitonin 41
1.5.3.5 Retinoblastoma 41
1.5.3.6 Von Hippel Lindau 42
1.5.3.7 p16 and p15 42
1.5.3.8 Methylation as a Therapeutic Target 43
1.5.4 DNA Methylation in the Promoter Region of ABO 44
1.6 Aims 45

Chapter 2 Materials and Methods
2.1 Materials 47
2.1.1 List of Primers 51
2.2 General Molecular Biology Methods 55
2.2.1 DNA Extraction from Peripheral Blood Mononuclear Cells 55
2.2.2 Preparation of Genomic DNA and RNA from Bone Marrow
2.2.3 Isolation of DNA and RNA from Peripheral Blood Stem Cells (PBSCs)
2.2.4 Isolation of DNA from Frozen Blood
2.2.5 Quantitation of DNA and RNA
2.2.6 DNA Precipitation
2.3 Cell Culture Methods
2.3.1 Thawing Cells
2.3.2 Maintenance and Subculturing of Cells
2.3.3 Viability Tests
2.3.4 Freezing Cells
2.3.5 5-Aza-2'-Deoxycytidine Treatments
2.4 Spherical Red Blood Cells and Flow Cytometric Methods
2.4.1 Making Formalin Fixed Spherical Red Blood Cells
2.4.2 Labelling Spherical Red Blood Cells
2.4.3 Flow Cytometric Analysis
2.5 Polymerase Chain Reaction Methods
2.5.1 Primer Design
2.5.2 PCR Reaction and Conditions
2.5.3 Purification of PCR Products
2.5.4 Restriction Enzyme Digestion of PCR Products
2.5.5 Reverse Transcription
2.5.6 DNase I Treatment of RNA
2.5.7 Agarose Gel Electrophoresis
2.5.8 Sequencing of PCR Products
2.6 Methylation Analysis Methods
2.6.1 Bisulphite Modification of DNA
2.6.2 Primer Design
2.6.3 PCR of Bisulphite Modified DNA and MDE Gel Electrophoresis
2.6.4 Band Stabs and Sequencing
2.7 Northern Blotting Methods 65
  2.7.1 Generation of Probes 65
  2.7.2 RNA Gel Electrophoresis and Blotting 65
  2.7.3 Hybridisation 66
2.8 Southern Blotting Methods 66
  2.8.1 Restriction Digests 66
  2.8.2 Gel Electrophoresis 66
  2.8.3 DNA Transfer to Nylon Membrane 67
  2.8.4 Hybridisation 67
  2.8.5 Washing the Membranes 67

Chapter 3 Flow Cytometric Analysis of ABH Antigens 69
  3.1 Introduction 71
  3.2 Results 71
    3.2.1 Normal Individuals 71
      3.2.1.1 Flow Patterns in O and Bombay Individuals 71
      3.2.1.2 Flow Patterns in B Individuals 71
      3.2.1.3 Flow Patterns in A Individuals 73
      3.2.1.4 Flow Patterns in Weak A Individuals 74
      3.2.1.5 Flow Patterns in AB Individuals 77
    3.2.2 AML and MDS Patients 81
      3.2.2.1 Loss of the H Antigen 86
      3.2.2.2 Loss of A or B Antigen 88
      3.2.2.3 Loss of H and A or B Antigens 90
    3.2.3 Other Patients Analysed by Flow Cytometry 92
  3.3 Discussion 94

Chapter 4 ABO and FUT1 Genotyping and Expression Analysis 105
  4.1 Introduction iv
4.2 Results

4.2.1 Genotyping of ABO
   4.2.1.1 Genotyping for the O' Allele
   4.2.1.2 Genotyping for the A' Allele
   4.2.1.3 Genotyping for the B Allele
   4.2.1.4 Genotyping for the O' Allele
   4.2.1.5 Patient Genotyping Results

4.2.2 Expression of ABO
   4.2.2.1 Alternative Splicing of the ABO mRNA
   4.2.2.2 ABO Expression in Normal PB MNCs and PBSCs
   4.2.2.3 ABO Expression in BM
   4.2.2.4 The RT-ABO PCR Product
   4.2.2.5 ABO Allelic Expression in Patients

4.2.3 Expression of FUT1
   4.2.3.1 Introduction
   4.2.3.2 Northern Analysis of FUT1
   4.2.3.3 RT-PCR Analysis of the Alternative Transcripts of FUT1

4.3 Discussion

Chapter 5 ABO and FUT1 Epigenetic Analysis

5.1 Introduction

5.2 Results
   5.2.1 Methylation Status of the ABO Promoter by Southern Analysis
   5.2.2 MS-SSCA: the Development of a New Methylation Analysis Technique
      5.2.2.1 MS-SSCA of the ABO Promoter
      5.2.2.2 FUT1 MS-SSCA
      5.2.3 5-Aza-2'-Deoxycytidylate Treatment on Leukaemic Cell Lines

5.3 Discussion
Chapter 6 Analysis of 9q34 Genes

6.1 Introduction 196
6.2 Results 199
   6.2.1 Genotyping SNPs at 9q34 Loci 199
      6.2.1.1 9q34 SNP Analysis in Normal Individuals 200
      6.2.1.2 9q34 SNP Analysis in Leukaemic Cell Lines 204
      6.2.1.3 9q34 SNP Analysis in Leukemic Patients 205
   6.2.2 Expression of 9q34 Loci SNPs 207
      6.2.2.1 9q34 Loci Expression in Normal Individuals and Leukaemic Cell Lines 211
      6.2.2.2 9q34 Loci Expression in Leukaemic Patients 211
6.3 Discussion 217

Chapter 7 Conclusion and Future Directions

7.1 Conclusion 221
7.2 Future Directions 226

References 229
Abstract

This thesis describes the investigation of the alteration of ABH antigen expression on the surface of red blood cells in patients with haematological malignancies. ABH antigens are complex carbohydrates present on the surface of erythrocytes. These antigens are generated by the stepwise addition of monosaccharides, with each step catalysed by a specific glycosyltransferase. The A and B alleles of the ABO locus encode the A and B glycosyltransferases, which act on the precursor H antigen to produce the A and B antigens. The precursor H antigen is determined by a fucosyltransferase coded for by the FUT1 locus.

A flow cytometric technique was developed to analyse the red blood cells of patients for changes in ABH antigen expression. In normal individuals flow cytometric profiles were associated with particular ABO genotypes. Nearly 50% of patients had some alteration of the A, B or H antigens.

RT-PCR was used to investigate ABO mRNA expression in bone marrow (BM) cells of patients with alterations in ABH antigens. Of eleven patients with loss of A or B antigens detected by flow cytometry, only 3 had loss at the mRNA level. The lack of correlation between loss on the flow cytometer and loss at the mRNA level was not surprising as the population with loss was often small and the predominant normal population would mask any losses.

The expression of FUT1 mRNA was also investigated using RT-PCR. FUT1 has three transcripts arising from three different transcription initiation start sites. The individual expression of each transcript was assessed by RT-PCR in normal individuals and in patients with loss of ABH antigens. It was found that the exon 2 transcript is the most important in determining H antigen expression.
The molecular mechanisms underlying loss of ABH antigens were investigated by assessing CpG methylation of the ABO and FUT1 promoters, and by assessing loss of heterozygosity (LOH) of genes adjacent to ABO. Treatment of leukaemia cell lines, which did not express ABO, with a demethylating agent led to re-expression of ABO. There was no association between patients with loss of ABH antigens and ABO methylation. However, of 7 patients with loss of ABH antigens detected in a previous PhD study, 5 were methylated in this study. This difference may be attributable to a greater majority of cells (>50%) with loss of ABH antigens in the samples detected previously compared to the samples in this study.

LOH of genes adjacent to ABO on the chromosomal region 9q34 was investigated. This chromosomal region has been shown to be frequently lost in acute myeloid leukaemia. Single nucleotide polymorphisms in various 9q34 loci, were assessed for LOH by a PCR-RFLP method. Samples from 42% of patients showed loss of expression in the tumour suppressor gene DAPK1. Two less well-known genes, POMTI and PPP2R4, had allele dosage alterations in patient samples.

In conclusion, loss of ABH antigens in haematological malignancies is a frequent event. Loss of cell surface ABH antigen expression is a marker for alterations at other 9q loci besides ABO, suggesting that this region harbours potential tumour suppressor genes or that 9q undergoes regional silencing.